<DOC>
	<DOCNO>NCT02795182</DOCNO>
	<brief_summary>This study evaluate safety preliminary efficacy BGB-3111 combination BGB-A317 subject B-cell lymphoid malignancy .</brief_summary>
	<brief_title>BGB-3111 Combination With BGB-A317 Subjects With B-cell Malignancies</brief_title>
	<detailed_description />
	<criteria>Aged ≥ 18 year , able willing provide write informed consent comply study protocol . Laboratory parameter specify : Hematologic : platelet count &gt; 50 x 10e9/L ; absolute neutrophil count &gt; 1.0 x109 cells/L ; Hepatic : total Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; aspartate aminotransaminase ( AST ) alanine aminotransaminase ( ALT ) ≤ 3x ULN Renal : creatinine clearance ≥ 30 mL/min ; subject require hemodialysis exclude . Anticipated survival least 4 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Female subject childbearing potential nonsterile male must practice least one follow method birth control partner ( ) throughout study ≥ 3 month discontinue study drug : total abstinence sexual intercourse , doublebarrier contraception , intrauterine device hormonal contraceptive initiate least 3 month prior first dose study drug . Male subject must donate sperm initial study drug administration , 180 day drug discontinuation . Known , active , central nervous system lymphoma leukemia Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenia purpura History stroke cerebral hemorrhage within 6 month enrollment History significant cardiovascular disease , define : Congestive heart failure great New York Heart Association ( NYHA ) class II accord NYHA functional classification Unstable angina myocardial infarction 6 month enrollment Severe debilitate pulmonary disease ( dyspnea rest , significant shortness breath , congestive obstructive pulmonary disease ) History severe allergic anaphylactic reaction monoclonal antibody therapy Prior Bruton 's tyrosine kinase ( BTK ) inhibitor anti program cell death1 ( PD1 ) /antiProgrammed Death Ligand1 ( PDL1 ) treatment . History interstitial lung disease noninfectious pneumonitis except induced radiation therapy Vaccination live vaccine within 28 day initiation treatment . Participated investigational drug study within 28 day recover toxicity prior chemotherapy grade ≤ 1 . Major surgery past 4 week Active symptomatic fungal , bacterial and/or viral infection include evidence infection human immunodeficiency virus ( HIV ) , human Tcell lymphotropic virus type 1 seropositive status Inability comply study procedure Pregnant nurse woman Men woman childbearing potential refuse use adequate measure contraception unless past medical history surgical sterilization . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>